作者: Brian T. Helfand , William J. Catalona , Jianfeng Xu
DOI: 10.1097/MOU.0000000000000130
关键词:
摘要: Purpose Recent advances in sequencing technologies has allowed for the identification of genetic variants within germline DNA that can explain a significant portion underpinnings prostate cancer. Despite evidence suggesting these be used improved risk stratification, they have not yet been routinely incorporated into routine clinical practice. This review highlights their potential utility cancer screening.